DailyStocks Stock Article Search

https://www.rttnews.com/story.aspx?Id=3428203 Feb 28, 2024 - Applied Therapeutics, Inc. (APLT), Wednesday announced that the U.S. Food and Drug Administration had accepted the filing of the New Drug Application or NDA for Govorestat for the treatment of galactosemia and granted a priority review. 0

https://www.zacks.com/stock/news/2222976/mid-america-apartment-communities-maa-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2222976 Feb 07, 2024 - While the top- and bottom-line numbers for Mid-America Apartment Communities (MAA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2221904/what-s-in-the-cards-for-kimco-kim-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221904 Feb 06, 2024 - The resilient demand for Kimco's (KIM) grocery-anchored centers, a diverse tenant base and a focus on mixed-use assets are likely to have aided its Q4 earnings despite higher interest expenses. 0

https://www.fool.com/investing/2024/01/08/3-stocks-that-make-the-perfect-investment-for-the/?source=iedfolrf0000001 Jan 08, 2024 - These REITs can reliably roll in the income while you reel in the years. 0

https://www.fool.com/investing/2023/12/26/bull-market-buys-3-dividend-stocks-to-own-for-the/?source=iedfolrf0000001 Dec 26, 2023 - These dividend stocks could start their own bull run in 2024 as their headwind fades. 0

https://www.zacks.com/stock/news/2200597/anavex-avxl-rises-as-chmp-deems-blarcamesine-eligible-for-maa?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200597 Dec 20, 2023 - The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise. 0

https://www.fool.com/investing/2023/12/12/10-of-the-best-reits-for-2024/?source=iedfolrf0000001 Dec 12, 2023 - REITs are expected to rebound in 2024. 0